141 related articles for article (PubMed ID: 14690246)
1. A capillary electrophoresis technique for evaluating botulinum neurotoxin B light chain activity.
Adler M; Shafer HF; Manley HA; Hackley BE; Nicholson JD; Keller JE; Goodnough MC
J Protein Chem; 2003 Jul; 22(5):441-8. PubMed ID: 14690246
[TBL] [Abstract][Full Text] [Related]
2. Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments.
Foran P; Shone CC; Dolly JO
Biochemistry; 1994 Dec; 33(51):15365-74. PubMed ID: 7803399
[TBL] [Abstract][Full Text] [Related]
3. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution.
Hanson MA; Stevens RC
Nat Struct Biol; 2000 Aug; 7(8):687-92. PubMed ID: 10932255
[TBL] [Abstract][Full Text] [Related]
4. Production of an expression system for a synaptobrevin fragment to monitor cleavage by botulinum neurotoxin B.
Nowakowski JL; Courtney BC; Bing QA; Adler M
J Protein Chem; 1998 Jul; 17(5):453-62. PubMed ID: 9717740
[TBL] [Abstract][Full Text] [Related]
5. Rapid microplate assay for monitoring botulinum neurotoxin B catalytic activity.
Keller JE; Nowakowski JL; Filbert MG; Adler M
J Appl Toxicol; 1999 Dec; 19 Suppl 1():S13-7. PubMed ID: 10594893
[TBL] [Abstract][Full Text] [Related]
6. Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin.
Chen S; Hall C; Barbieri JT
J Biol Chem; 2008 Jul; 283(30):21153-9. PubMed ID: 18511417
[TBL] [Abstract][Full Text] [Related]
7. Peptide substrate specificity and properties of the zinc-endopeptidase activity of botulinum type B neurotoxin.
Shone CC; Roberts AK
Eur J Biochem; 1994 Oct; 225(1):263-70. PubMed ID: 7925446
[TBL] [Abstract][Full Text] [Related]
8. A yeast assay probes the interaction between botulinum neurotoxin serotype B and its SNARE substrate.
Fang H; Luo W; Henkel J; Barbieri J; Green N
Proc Natl Acad Sci U S A; 2006 May; 103(18):6958-63. PubMed ID: 16636286
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of botulinum neurotoxin serotype H as a hybrid of known serotypes F and A (BoNT F/A).
Kalb SR; Baudys J; Raphael BH; Dykes JK; Lúquez C; Maslanka SE; Barr JR
Anal Chem; 2015 Apr; 87(7):3911-7. PubMed ID: 25731972
[TBL] [Abstract][Full Text] [Related]
10. VAMP/synaptobrevin cleavage by tetanus and botulinum neurotoxins is strongly enhanced by acidic liposomes.
Caccin P; Rossetto O; Rigoni M; Johnson E; Schiavo G; Montecucco C
FEBS Lett; 2003 May; 542(1-3):132-6. PubMed ID: 12729912
[TBL] [Abstract][Full Text] [Related]
11. Proteolytic cleavage of synthetic fragments of vesicle-associated membrane protein, isoform-2 by botulinum type B neurotoxin.
Shone CC; Quinn CP; Wait R; Hallis B; Fooks SG; Hambleton P
Eur J Biochem; 1993 Nov; 217(3):965-71. PubMed ID: 8223654
[TBL] [Abstract][Full Text] [Related]
12. Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity.
Schmidt JJ; Stafford RG
Biochemistry; 2005 Mar; 44(10):4067-73. PubMed ID: 15751983
[TBL] [Abstract][Full Text] [Related]
13. The interaction of synaptic vesicle-associated membrane protein/synaptobrevin with botulinum neurotoxins D and F.
Pellizzari R; Mason S; Shone CC; Montecucco C
FEBS Lett; 1997 Jun; 409(3):339-42. PubMed ID: 9224685
[TBL] [Abstract][Full Text] [Related]
14. Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities.
Hallis B; James BA; Shone CC
J Clin Microbiol; 1996 Aug; 34(8):1934-8. PubMed ID: 8818885
[TBL] [Abstract][Full Text] [Related]
15. Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin.
Schiavo G; Shone CC; Rossetto O; Alexander FC; Montecucco C
J Biol Chem; 1993 Jun; 268(16):11516-9. PubMed ID: 8505288
[TBL] [Abstract][Full Text] [Related]
16. Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage.
Vaidyanathan VV; Yoshino K; Jahnz M; Dörries C; Bade S; Nauenburg S; Niemann H; Binz T
J Neurochem; 1999 Jan; 72(1):327-37. PubMed ID: 9886085
[TBL] [Abstract][Full Text] [Related]
17. Specificity of botulinum protease for human VAMP family proteins.
Yamamoto H; Ida T; Tsutsuki H; Mori M; Matsumoto T; Kohda T; Mukamoto M; Goshima N; Kozaki S; Ihara H
Microbiol Immunol; 2012 Apr; 56(4):245-53. PubMed ID: 22289120
[TBL] [Abstract][Full Text] [Related]
18. High level expression of the light chain of botulinum neurotoxin serotype C1 and an efficient HPLC assay to monitor its proteolytic activity.
Rawat R; Ashraf Ahmed S; Swaminathan S
Protein Expr Purif; 2008 Aug; 60(2):165-9. PubMed ID: 18482846
[TBL] [Abstract][Full Text] [Related]
19. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
Arndt JW; Chai Q; Christian T; Stevens RC
Biochemistry; 2006 Mar; 45(10):3255-62. PubMed ID: 16519520
[TBL] [Abstract][Full Text] [Related]
20. Buforin I, a natural peptide, inhibits botulinum neurotoxin B activity in vitro.
Garcia GE; Moorad DR; Gordon RK
J Appl Toxicol; 1999 Dec; 19 Suppl 1():S19-22. PubMed ID: 10594894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
